{
  "id": "5c6f107c7c78d69471000051",
  "type": "list",
  "question": "Which molecules are targeted by defactinib?",
  "ideal_answer": "PURPOSE: VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26530902",
    "http://www.ncbi.nlm.nih.gov/pubmed/30444612",
    "http://www.ncbi.nlm.nih.gov/pubmed/29145097",
    "http://www.ncbi.nlm.nih.gov/pubmed/27025608",
    "http://www.ncbi.nlm.nih.gov/pubmed/26334219",
    "http://www.ncbi.nlm.nih.gov/pubmed/29314097",
    "http://www.ncbi.nlm.nih.gov/pubmed/28881794"
  ],
  "snippets": [
    {
      "text": "LC-ESI-MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145097",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29314097",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Focal Adhesion Kinase (FAK) activation is a mediator of docetaxel resistance in prostate cancer cells. The aim of this study was to investigate the effect of the second generation FAK inhibitor VS-6063 on docetaxel efficacy in pre-clinical CRPC and CSPC models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29314097",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we report the development of a selective and potent Fak degrader, PROTAC-3, which outperforms a clinical candidate, defactinib, with respect to Fak activation as well as Fak-mediated cell migration and invasion. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30444612",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Prompted by our observation of a correlation between PTEN loss and FAK phosphorylation in a cohort of patients with stage IV SCC, we evaluated the relevance of PTEN loss in cancer progression as well as the efficacy of a new combined treatment with the pan PI3K inhibitor buparlisip and the FAK inhibitor defactinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28881794",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26334219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Accordingly, treatment of C4-2B4 cells with integrin ligands resulted in increased pFAK-Y397 expression and cell survival, whereas targeting integrins with FAK inhibitors PF-562271 or defactinib inhibited FAK phosphorylation and reduced the survival of PC3-mm2 cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530902",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nVS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26334219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE\nVS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26334219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Accordingly, treatment of C4-2B4 cells with integrin ligands resulted in increased pFAK-Y397 expression and cell survival, whereas targeting integrins with FAK inhibitors PF-562271 or defactinib inhibited FAK phosphorylation and reduced the survival of PC3-mm2 cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530902",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Accordingly, treatment of C4-2B4 cells with integrin ligands resulted in increased pFAK-Y397 expression and cell survival, whereas targeting integrins with FAK inhibitors PF-562271 or defactinib inhibited FAK phosphorylation and reduced the survival of PC3-mm2 cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530902",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "focal adhesion kinase, proline-rich tyrosine kinase-2"
}